Influence of Home Monitoring on the Clinical Status of Heart Failure Patients
IN-TIME is the first randomized trial to demonstrate a reduction in mortality in heart failure patients with implant-based remote monitoring.
- Randomized, controlled, international, multicenter study
- To assess the impact of BIOTRONIK Home Monitoring® on the clinical status of heart failure patients.
- 664 patients at 36 centers
Key Result 1
At 12 months follow-up, significantly fewer patients in the BIOTRONIK Home Monitoring® group worsened according to the modified Packer score compared to the control group (18.9% vs27.5%; p>
- > 30% Risk Reduction for Worsening of Clinical Status
Key Result 2
Significant reduction of all-cause mortality in heart failure patients (> 50 %) and beneficial effect on the composite clinical score with implant-based (ICD or CRT-D) BIOTRONIK Home Monitoring® compared to standard care.
- The IN-TIME study demonstrated improved clinical status for heart failure patients by implementing a remote monitoring system based on:
- A reliable transmission rate of 85%
- A clinically relevant set of rhythmological and technical parameters
- Clinical workflow that enables fast patient contact and follow-up within one to two working days
- The European Society of Cardiology added a clear recommendation for the use of implant-based remote follow-up to its guidelines.1
|Main Exclusion Criteria||
Cardiac Resynchronization Therapy
BIOTRONIK offers an extensive product portfolio in the area of Cardiac Resynchronization.
Cardiac Remote Monitoring
BIOTRONIK offers Home Monitoring for its complete product portfolio.
1 Brignole M et al. 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. European Heart Journal. 2013, 34(29)